Stockreport

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte, Inc.  (PCVX) 
PDF -- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce T [Read more]